Tempero Bio has raised $70 million in Series B financing to advance TMP-301, a novel mGluR5 negative allosteric modulator targeting the neurobiological basis of addiction, through Phase 2 clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.